ArticleBMC genetics2016
ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population.
Article in BMC genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Advances in statin adverse reactions and the potential mechanisms: A systematic review.Journal of advanced research · 2025Pooled it
- HLA and non-HLA genetic analyses reveal suggestive variants associated with statin-induced liver injury.Hepatology communications · 2026Article
- ABCG2 transporter: Structural and functional associations with gout (Review).International journal of molecular medicine · 2026Review
- Association of p-glycoprotein and bile salt export pump gene polymorphisms with advanced liver disease in hepatitis C virus infected patients.Memorias do Instituto Oswaldo Cruz · 2026Article
- Cost-Effectiveness Analysis of Pitavastatin in Dyslipidemia: Vietnam Case.Healthcare (Basel, Switzerland) · 2025Article
- Atorvastatin-Induced Liver Injury With Concurrent Rhabdomyolysis After a Positive Rechallenge.ACG case reports journal · 2025Article
- Molecular and Clinical Links between Drug-Induced Cholestasis and Familial Intrahepatic Cholestasis.International journal of molecular sciences · 2023Review
- Association betweenJournal of personalized medicine · 2021Review
- Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review.Arhiv za higijenu rada i toksikologiju · 2021Review
- MassARRAY multigene screening combined with LDL-C and sdLDL-C detection for more favorable outcomes in type 2 diabetes mellitus therapy.BMC medical genomics · 2021Article
- Research Progress of Pharmacogenomics in Drug-Induced Liver Injury.Frontiers in pharmacology · 2021Review
- Article
- An Integrated Approach Exploring the Synergistic Mechanism of Herbal Pairs in a Botanical Dietary Supplement: A Case Study of a Liver Protection Health Food.International journal of genomics · 2020Article
- Article
- Association of atorvastatin with the risk of hepatotoxicity: a pilot prescription sequence symmetry analysis.Therapeutics and clinical risk management · 2019Article
- Quantitative Evaluation of Drug Resistance Profile of Cells Expressing Wild-Type or Genetic Polymorphic Variants of the Human ABC Transporter ABCC4.International journal of molecular sciences · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the associations between atorvastatin-induced liver injury (AILI) and polymorphisms in eight genes possibly involved in the hepatic metabolism (CYP2C9, CYP2C19, CYP3A4, CYP3A5 and UGT1A1) and membrane transport (ABCB1, ABCG2 and SLCO1B1) of atorvastatin, we genotyped 30 AILI and 414 non-AILI patients recruited at BioBank Japan for 15 single nucleotide polymorphisms (SNPs).
resultsAn SNP in ABCB1 (rs2032582: 2677G > T/A) was significantly associated with AILI (P = 0.00068, odds ratio (OR) = 2.59 with 95 % confidence interval (CI) of 1.49-4.50, G allele versus T and A alleles), indicating that the G allele might be a risk factor for AILI. The cytotoxicity test demonstrated that IC50 value of atorvastatin to inhibit the growth and/or viability of Flp-In-293/ABCB1 (2677G) cells was 5.44 ± 0.10 mM, which was significantly lower than those in Flp-In-293/ABCB1 (2677 T) (6.02 ± 0.07 mM) and Flp-In-293/ABCB1 (2677A) cells (5.95 ± 0.08 mM).
conclusionsThese results indicate that ABCB1 rs2032582 may predict the risk of AILI in Japanese population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.